SHARE

Halozyme Therapeutics, Inc. (NASDAQ:HALO), a novel oncology and drug delivery based biotechnology company, announced that it has dosed its first patent in Phase 3 clinical trial (Halo-301 | Pancreatic study) on pancreatic cancer patients.

Insights of Matter

The international, double-blind, randomized trial study will collect all the information about PEGPH20 – Halozyme’s investigational drug, along with gemcitabine and ABRAXANE in those patients who carry high chances of hyaluronan. It’s a chain of natural sugars or glycosaminoglycan that can easily impede the access of drugs, which target tumors.

The new PEGPH20 degrades HA for some time. It has been used in animal models to check whether it can improve the concentration of co-administered therapies in any particular tumor. So far the results are positive, and the management team of Halozyme Therapeutics is delighted to see these initial findings and hopes that things will continue to fall in line in the coming months as well.

In addition to this, Halozyme also unveiled that the investigational device exemption that it had submitted to U.S. Food and Drug Administration by its partner company Ventana Medical Systems has been approved without any hassle. With the help of IDE, Halozyme can use Ventana HA CDx Assay without any complexity in companion diagnostic Halo-301. It can further help the company to identify HA-High patients easily and include them in the trial.

The start of Phase 3 Study of PEGPH20 in HA-High pancreatic cancer patients is a milestone for PEGPH20 development program as well as the entire senior management team of the company. In the opinion of Dr. Margaret Tempero, Director, Pancreas Center – University of California, high HA level can be seen as a sign of below-expectations progress in many cancer patients.

It will continue to come up with more such products in the coming months and make it easier for the patients to live a healthy and long life.

SHARE
Previous articleCerus Corporation (NASDAQ:CERS) Receives Green Signal From FDA For INTERCEPT Blood System
Next articleJury Favors Amgen, Inc. (NASDAQ:AMGN) In Patent Infringement Case Against Sanofi And Regeneron Pharmaceuticals
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.

LEAVE A REPLY